All In Biotech

NDA 203284 · Horizon Therap US

Ravicti

Glycerol Phenylbutyrate · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Sep 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Feb 1, 2013

Approved uses

5

Original approval plus efficacy supplements

Registered trials

21

4 Phase 3, 3 recruiting

FAERS reports

1,392

843 serious, 66 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2025.

RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). Limitations of Use: RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels. The safety and efficacy of RAVICTI for the treatment of N- acetylglutamate synthase (NAGS) deficiency has not been established. RAVICTI is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements. ( 1 ) Limitations of Use : RAVICTI is not indicated for treatment of acute hyperammonemia in patients with UCDs. ( 1 ) Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established. ( 1 )

Mechanism: UCDs are inherited deficiencies of enzymes or transporters necessary for the synthesis of urea from ammonia (NH 3 , NH 4 + ). Absence of these enzymes or transporters results in the accumulation of toxic levels of ammonia in the blood and brain of affected patients. RAVICTI is a triglyceride containing 3 molecules of PBA. PAA, the major metabolite of PBA, is the active moiety of RAVICTI. PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form PAGN, which is excreted by the kidneys (Figure 1). On a molar basis, PAGN, like urea,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RAVICTI · GLYCEROL PHENYLBUTYRATE 1.1GM/ML · LIQUID, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Glycerol Phenylbutyrate" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ammonia increased207
  • vomiting168
  • hyperammonaemia166
  • decreased appetite106
  • nausea74
  • headache66
  • hyperammonaemic crisis64
  • off label use63
  • diarrhoea58
  • fatigue53
  • somnolence53
  • weight decreased47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20139
201420
2015270
2016260
2017102
201881
201996
202063
202129
202233
2023106
2024193
202543
202687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 1, 2026

    RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-06). Discontinuation in the manufacturing of the drug product

  • To Be Discontinued · updated Sep 1, 2026

    RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-07). Discontinuation in the manufacturing of the drug product

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ravicti (Glycerol Phenylbutyrate)

2024 spending

$79.5M

Beneficiaries

94

928 claims

Per beneficiary

$845,247

$222.68 per unit

View as table
YearSpending
2020$53,970,031
2021$60,056,340
2022$66,453,447
2023$73,454,459
2024$79,453,177

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.